Mark McGurk
Corporate Officer/Principal presso King's College London
Posizioni attive di Mark McGurk
Società | Posizione | Inizio | Fine |
---|---|---|---|
King's College London | Corporate Officer/Principal | - | - |
Storia della carriera di Mark McGurk
Precedenti posizioni note di Mark McGurk
Società | Posizione | Inizio | Fine |
---|---|---|---|
Odontis Ltd.
Odontis Ltd. Miscellaneous Commercial ServicesCommercial Services Odontis is developing a biological replacement tooth product - the BioToothTM. The research is lead by Professor Paul Sharpe at King's College London Dental Institute. His team has demonstrated that tooth development can be initiated in stem cells, and that fully formed teeth can be created in developmental models. This is pioneering in that it represents one of the very few examples of a fully integrated tissue engineered organ. The technology opens the potential for the implantation of cultured cells in patients to grow and replace damaged or missing teeth. Odontis has attracted over £2 million of funding to date to progress the technology to commercial development. | Corporate Officer/Principal | - | 18/01/2011 |
The University of Manchester | Corporate Officer/Principal | - | - |
Statistiche
Distribuzione geografica
Regno Unito | 3 |
Israele | 2 |
Posizioni
Corporate Officer/Principal | 3 |
Settori
Consumer Services | 3 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
Odontis Ltd.
Odontis Ltd. Miscellaneous Commercial ServicesCommercial Services Odontis is developing a biological replacement tooth product - the BioToothTM. The research is lead by Professor Paul Sharpe at King's College London Dental Institute. His team has demonstrated that tooth development can be initiated in stem cells, and that fully formed teeth can be created in developmental models. This is pioneering in that it represents one of the very few examples of a fully integrated tissue engineered organ. The technology opens the potential for the implantation of cultured cells in patients to grow and replace damaged or missing teeth. Odontis has attracted over £2 million of funding to date to progress the technology to commercial development. | Commercial Services |
- Borsa valori
- Insiders
- Mark McGurk
- Esperienza